Luca Gattinoni

List of Publications by Year
in descending order

112 papers	20,321 citations	17429 63 h-index	27389 106 g-index
115 all docs	115 docs citations	115 times ranked	20842 citing authors

#	Article	IF	Citations
1	A human memory T cell subset with stem cellâ€“like properties. Nature Medicine, 2011, 17, 1290-1297.	15.2	1,547
2	Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. Journal of Experimental Medicine, 2005, 202, 907-912.	4.2	951
3	Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nature Medicine, 2009, 15, 808-813.	15.2	839
4	Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells. Journal of Clinical Investigation, 2005, 115, 1616-1626.	3.9	815
5	Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 9571-9576.	3.3	810
6	Adoptive immunotherapy for cancer: building on success. Nature Reviews Immunology, 2006, 6, 383-393.	10.6	801
7	Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood, 2008, 112, 362-373.	0.6	719
8	Inhibiting glycolytic metabolism enhances CD8+ T cell memory and antitumor function. Journal of Clinical Investigation, 2013, 123, 4479-4488.	3.9	719
9	IL-15 enhances thein vivoantitumor activity of tumor-reactive CD8+T Cells. Proceedings of the National Academy of Sciences of the United States of America, 2004, 101, 1969-1974.	3.3	499
10	Paths to stemness: building the ultimate antitumour T cell. Nature Reviews Cancer, 2012, 12, 671-684.	12.8	487
11	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 2197-2204.	3.9	456
12	CD8 + Tâ€cell memory in tumor immunology and immunotherapy. Immunological Reviews, 2006, 211, 214-224.	2.8	434
13	The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Science Immunology, 2016, 1, .	5.6	415
14	T memory stem cells in health and disease. Nature Medicine, 2017, 23, 18-27.	15.2	396
15	Th17 Cells Are Long Lived and Retain a Stem Cell-like Molecular Signature. Immunity, 2011, 35, 972-985.	6.6	392
16	IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood, 2008, 111, 5326-5333.	0.6	380
17	Single-cell RNA-seq reveals TOX as a key regulator of CD8+ T cell persistence in chronic infection. Nature Immunology, 2019, 20, 890-901.	7.0	361
18	Adoptively transferred effector cells derived from naÃ¯ve rather than central memory CD8 ⁺ T cells mediate superior antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 17469-17474.	3.3	348

#	Article	IF	Citations
19	BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis. Nature, 2013, 498, 506-510.	13.7	332
20	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy. Cell Metabolism, 2016, 23, 63-76.	7.2	291
21	Superior T memory stem cell persistence supports long-lived T cell memory. Journal of Clinical Investigation, 2013, 123, 594-9.	3.9	287
22	Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics. Cancer Research, 2015, 75, 296-305.	0.4	283
23	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. Immunity, 2013, 38, 742-753.	6.6	278
24	Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood, 2016, 128, 519-528.	0.6	274
25	Human effector CD8+ T cells derived from naive rather than memory subsets possess superior traits for adoptive immunotherapy. Blood, 2011, 117, 808-814.	0.6	272
26	High-Efficiency Transfection of Primary Human and Mouse T Lymphocytes Using RNA Electroporation. Molecular Therapy, 2006, 13, 151-159.	3.7	260
27	Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice. Clinical Cancer Research, 2011, 17, 5343-5352.	3.2	247
28	Sorting Through Subsets. Journal of Immunotherapy, 2012, 35, 651-660.	1.2	237
29	Increased Intensity Lymphodepletion Enhances Tumor Treatment Efficacy of Adoptively Transferred Tumor-specific T Cells. Journal of Immunotherapy, 2010, 33, 1-7.	1.2	236
30	Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts. Cancer Research, 2010, 70, 6725-6734.	0.4	227
31	BACH2 regulates CD8+ T cell differentiation by controlling access of AP-1 factors to enhancers. Nature Immunology, 2016, 17, 851-860.	7.0	221
32	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8+ effector and memory T cell populations during infection. Journal of Experimental Medicine, 2015, 212, 2027-2039.	4.2	206
33	Oxygen Sensing by T Cells Establishes an Immunologically Tolerant Metastatic Niche. Cell, 2016, 166, 1117-1131.e14.	13.5	203
34	Safety and Efficacy of Two Different Doses of Capecitabine in the Treatment of Advanced Breast Cancer in Older Women. Journal of Clinical Oncology, 2005, 23, 2155-2161.	0.8	200
35	Memory T cellâ€"driven differentiation of naive cells impairs adoptive immunotherapy. Journal of Clinical Investigation, 2015, 126, 318-334.	3.9	193
36	Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nature Protocols, 2013, 8, 33-42.	5.5	181

#	Article	IF	Citations
37	Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8+ T cells. Journal of Clinical Investigation, 2007, 117, 492-501.	3.9	181
38	Lineage relationship of effector and memory T cells. Current Opinion in Immunology, 2013, 25, 556-563.	2.4	173
39	Two subsets of stem-like CD8+ memory T cell progenitors with distinct fate commitments in humans. Nature Immunology, 2020, 21, 1552-1562.	7.0	167
40	Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nature Immunology, 2011, 12, 1230-1237.	7.0	165
41	Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Research, 2011, 21, 1650-1658.	2.4	160
42	A Novel Chimeric Antigen Receptor Against Prostate Stem Cell Antigen Mediates Tumor Destruction in a Humanized Mouse Model of Pancreatic Cancer. Human Gene Therapy, 2014, 25, 1003-1012.	1.4	152
43	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. Journal of Experimental Medicine, 2015, 212, 2095-2113.	4.2	147
44	Wnt/Î²-Catenin Signaling in T-Cell Immunity and Cancer Immunotherapy. Clinical Cancer Research, 2010, 16, 4695-4701.	3.2	145
45	Inhibition of AKT signaling uncouples T cell differentiation from expansion for receptor-engineered adoptive immunotherapy. JCI Insight, 2017, 2, .	2.3	142
46	TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection. Cell Reports, 2015, 12, 2099-2110.	2.9	134
47	Lactate dehydrogenase inhibition synergizes with IL-21 to promote CD8 ⁺ T cell stemness and antitumor immunity. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 6047-6055.	3.3	128
48	Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nature Medicine, 2010, 16, 339-345.	15.2	122
49	Retinoic acid controls the homeostasis of pre-cDCâ€“derived splenic and intestinal dendritic cells. Journal of Experimental Medicine, 2013, 210, 1961-1976.	4.2	120
50	Toll-like Receptors in Tumor Immunotherapy. Clinical Cancer Research, 2007, 13, 5280-5289.	3.2	114
51	Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 8061-8066.	3.3	114
52	The transcription factor c-Myb regulates CD8+ T cell stemness and antitumor immunity. Nature Immunology, 2019, 20, 337-349.	7.0	113
53	Vaccine-Stimulated, Adoptively Transferred CD8+ T Cells Traffic Indiscriminately and Ubiquitously while Mediating Specific Tumor Destruction. Journal of Immunology, 2004, 173, 7209-7216.	0.4	110
54	T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. Journal of Clinical Investigation, 2019, 129, 1551-1565.	3.9	108

#	Article	IF	Citations
55	Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy. Blood, 2014, 124, 3490-3500.	0.6	103
56	miR-155 augments CD8 ⁺ T-cell antitumor activity in lymphoreplete hosts by enhancing responsiveness to homeostatic Î³ _c cytokines. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 476-481.	3.3	99
57	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular and Molecular Immunology, 2016, 13, 502-513.	4.8	99
58	Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity. Nature Communications, 2017, 8, 2125.	5.8	99
59	An engineered IL-2 partial agonist promotes CD8+ T cell stemness. Nature, 2021, 597, 544-548.	13.7	94
60	Extrathymic Generation of Tumor-Specific T Cells from Genetically Engineered Human Hematopoietic Stem Cells via Notch Signaling. Cancer Research, 2007, 67, 2425-2429.	0.4	87
61	Antioxidant metabolism regulates CD8+ T memory stem cell formation and antitumor immunity. JCI Insight, 2018, 3, .	2.3	84
62	Genetic Engineering of Murine CD8+ and CD4+ T Cells for Preclinical Adoptive Immunotherapy Studies. Journal of Immunotherapy, 2011, 34, 343-352.	1.2	80
63	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails. Cancer Immunology, Immunotherapy, 2013, 62, 727-736.	2.0	80
64	ONC201 kills breast cancer cells<i>in vitro</i>by targeting mitochondria. Oncotarget, 2018, 9, 18454-18479.	0.8	77
65	BACH2 enforces the transcriptional and epigenetic programs of stem-like CD8+ T cells. Nature Immunology, 2021, 22, 370-380.	7.0	75
66	T-Cell Receptor Gene Therapy of Established Tumors in a Murine Melanoma Model. Journal of Immunotherapy, 2008, 31, 1-6.	1.2	63
67	Programming CD8+ T cells for effective immunotherapy. Current Opinion in Immunology, 2006, 18, 363-370.	2.4	61
68	Pharmacologic Induction of CD8 ⁺ T Cell Memory: Better Living Through Chemistry. Science Translational Medicine, 2009, 1, 11ps12.	5.8	61
69	CTLA-4 dysregulation of self/tumor-reactive CD8+ T-cell function is CD4+ T-cell dependent. Blood, 2006, 108, 3818-3823.	0.6	59
70	Moving T memory stem cells to the clinic. Blood, 2013, 121, 567-568.	0.6	59
71	miR-155 harnesses Phf19 to potentiate cancer immunotherapy through epigenetic reprogramming of CD8+ T cell fate. Nature Communications, 2019, 10, 2157.	5.8	55
72	Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion. JCI Insight, 2017, 2, e90772.	2.3	54

#	Article	IF	Citations
73	The transcription factor BACH2 promotes tumor immunosuppression. Journal of Clinical Investigation, 2016, 126, 599-604.	3.9	49
74	InÂvitro generated anti-tumor T lymphocytes exhibit distinct subsets mimicking inÂvivo antigen-experienced cells. Cancer Immunology, Immunotherapy, 2011, 60, 739-749.	2.0	44
75	Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer. Journal of Leukocyte Biology, 2004, 76, 333-337.	1.5	43
76	Ex vivo AKT-inhibition facilitates generation of polyfunctional stem cell memory-like CD8+ T cells for adoptive immunotherapy. OncoImmunology, 2018, 7, e1488565.	2.1	41
77	Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood, 2008, 112, 4746-4754.	0.6	39
78	Enhancing adoptive T cell immunotherapy with microRNA therapeutics. Seminars in Immunology, 2016, 28, 45-53.	2.7	34
79	CXCR3 Identifies Human Naive CD8+ T Cells with Enhanced Effector Differentiation Potential. Journal of Immunology, 2019, 203, 3179-3189.	0.4	34
80	Transcriptional profiles reveal a stepwise developmental program of memory CD8+ T cell differentiation. Vaccine, 2015, 33, 914-923.	1.7	29
81	Transcriptional regulation of effector and memory CD8+ T cell fates. Current Opinion in Immunology, 2013, 25, 321-328.	2.4	27
82	Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination. Blood, 2009, 114, 1776-1783.	0.6	26
83	Identification of the Genomic Insertion Site of Pmel-1 TCR Î± and Î² Transgenes by Next-Generation Sequencing. PLoS ONE, 2014, 9, e96650.	1.1	24
84	Type I Cytokines Synergize with Oncogene Inhibition to Induce Tumor Growth Arrest. Cancer Immunology Research, 2015, 3, 37-47.	1.6	24
85	Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncology Reports, 2004, 12, 145-51.	1.2	24
86	Memory T Cells Officially Join the Stem Cell Club. Immunity, 2014, 41, 7-9.	6.6	19
87	Reply to: â€œÎ²-catenin does not regulate memory T cell phenotypeâ€• Nature Medicine, 2010, 16, 514-515.	15.2	18
88	Renal Cancer Treatment: A Review of the Literature. Tumori, 2003, 89, 476-484.	0.6	16
89	The New Old CD8+ T Cells in the Immune Paradox of Pregnancy. Frontiers in Immunology, 2021, 12, 765730.	2.2	13
90	Prognostic significance of cancer-testis gene expression in resected non-small cell lung cancer patients. Oncology Reports, 2004, 12, 145.	1.2	12

#	Article	IF	Citations
91	Short-term effects of anastrozole treatment on insulin-like growth factor system in postmenopausal advanced breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 2002, 80, 411-418.	1.2	11
92	The dark side of T memory stem cells. Blood, 2015, 125, 3519-3520.	0.6	8
93	Unusual Aspects of Melanoma. Journal of Clinical Oncology, 2004, 22, 745-746.	0.8	7
94	CD8+ T lymphocytes isolated from renal cancer patients recognize tumour cells through an HLA- and TCR/CD3-independent pathway. Cancer Immunology, Immunotherapy, 2007, 56, 1065-1076.	2.0	7
95	Lineage relationship of CD8+ T cell subsets is revealed by progressive changes in the epigenetic landscape. Cellular and Molecular Immunology, 0, , .	4.8	7
96	The short and sweet of T-cell therapy. OncoImmunology, 2014, 3, e27573.	2.1	6
97	Adoptive T cell transfer: Imagining the next generation of cancer immunotherapies. Seminars in Immunology, 2016, 28, 1-2.	2.7	6
98	Cancer cells hijack T-cell mitochondria. Nature Nanotechnology, 2022, 17, 3-4.	15.6	5
99	miR-155 releases the brakes on antitumor T cells. OncoImmunology, 2015, 4, e1026533.	2.1	4
100	Harnessing Stem Cell-Like Memory T Cells for Adoptive Cell Transfer Therapy of Cancer. Cancer Drug Discovery and Development, 2015, , 183-209.	0.2	4
101	Renal cancer treatment: a review of the literature. Tumori, 2003, 89, 476-84.	0.6	4
102	Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrozole or letrozole?. International Journal of Oncology, 2003, 22, 1081.	1.4	3
103	Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. Journal of Clinical Investigation, 2007, 117, 3140-3140.	3.9	2
104	Stubborn Tregs limit T-cell therapy. Blood, 2012, 120, 2352-2354.	0.6	2
105	Identification of tumor antigen-specific cytotoxic T lymphocytes cross-recognizing allogeneic major histocompatibility class I molecules. Tissue Antigens, 2000, 56, 19-29.	1.0	1
106	141â€ƒThe Role of T Memory Stem Cells. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 59.	0.9	1
107	T memory stem cell formation: Caveat mTOR. EBioMedicine, 2016, 4, 3-4.	2.7	0
108	International Regensburg Center for Interventional Immunology (RCI) symposium on â€œSynthetic immunology and environment-adapted redirection of T cellsâ€, 17â€"18 July, 2019, Regensburg, Germany. Cancer Immunology, Immunotherapy, 2020, 69, 677-682.	2.0	0

#	Article	IF	Citations
109	Partly MHC Matched Allogeneic Tumor Specific T Cells Mediate Tumor Regression without Inducing GVHD in Immunosuppressed Host.. Blood, 2006, 108, 5210-5210.	0.6	0
110	Treatment of Large Established Murine Melanoma with Th17 Polarized CD4+ T Helper Cells Genetically Engineered to Express MHC Class IIRestricted T Cell Receptor. Blood, 2008, 112, 3911-3911.	0.6	0
111	Akt Signalling Inhibition Promotes The Ex Vivo generation Of Minor Histocompatibility Antigen-Specific CD8+ Memory Stem T Cells. Blood, 2013, 122, 3269-3269.	0.6	0
112	Transcriptional repressor ZEB2 promotes terminal differentiation of CD8⁺ effector and memory T cell populations during infection. Journal of Cell Biology, 2015, 211, 2113OIA259.	2.3	0